Oncept IL-2

Authorised

This medicine is authorised for use in the European Union

feline interleukin-2 recombinant canarypox virus (vCP1338 virus)

Overview

Up-to-date information on this veterinary medicinal product is available on the Veterinary Medicines Information website

Oncept IL-2 : EPAR - Summary for the public

Product information

Oncept IL-2 : EPAR - Product Information

Oncept IL-2 : EPAR - All Authorised presentations

Product details

• Name of medicine:
  Oncept IL-2
• Active substance:
  Canarypox virus, strain vCP1338, expressing feline interleukin-2 gene, Live
• International non-proprietary name (INN) or common name:
  feline interleukin-2 recombinant canarypox virus (vCP1338 virus)

Pharmacotherapeutic group

• ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
• Immunostimulants
• Immunostimulants

Authorisation details

• EMA product number:
  EMEA/V/C/002562

Assessment history

Changes since initial authorisation of medicine

Oncept IL-2 : EPAR - Procedural steps taken and scientific information after authorisation

Initial marketing authorisation documents

Oncept IL-2 : EPAR - Public assessment report

Adopted

CVMP summary of positive opinion for Oncept IL-2

Adopted Reference Number: EMA/CVMP/100985/2013